News archive
Showing 654 results
September 2008
-
Media Release
RAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
- 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR Depot- 77% of patients with pancreatic NET… -
Media Release
RAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
-
Media Release
RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
-- Regulatory applications to be submitted worldwide for RAD001 first submissions filed in the Hidden List US, EU and Switzerland -- Data showing that RAD001 more than doubles time without tumor… -
Media Release
RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
July 2008
-
Media Release
Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
Jury verdict in Montgomery County Circuit Court awards $33 million in compensatory damagesJury decides in favor of Novartis and rejects claims for punitive damagesNPC maintains it reported true and… -
Media Release
Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
June 2008
-
Media Release
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
- Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Gleevec as standard of care- Study did not meet primary endpoint at 1 year,… -
Media Release
Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
-
Media Release
Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
May 2008
-
Media Release
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa® in Women With Early-Stage Breast Cancer
- Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36% beyond clinical benefits achieved with hormone therapy alone(1)- Findings… -
Media Release
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa® in Women With Early-Stage Breast Cancer